Introduction to Renin-Inhibitor
Renin is a proteolytic enzyme that is secreted in response to sympathetic activation, decreased sodium delivery and hypotension by the kidneys to the distal renal tubule. It converts angiotensinogen to angiotensin I, which is later converted to angiotensin II by angiotensin-converting enzyme. Angiotensin II is a potent vasoconstrictor that is responsible for blood pressure to rise. Renin-inhibitors are termed as a group of pharmaceutical drugs used primarily in the treatment of essential hypertension by blocking the activity of renin and causing vasodilatation. The first and second generations of drugs faced problems such as poor bioavailability and lack of potency whereas the third-generation drugs had acceptable oral bioavailability and were potent enough for clinical use. Aliskiren (INN) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.
Market Size and Forecast
The global renin-inhibitor market is projected to witness a robust growth owing to the rising awareness about hypertension with growing predominance, fixed-dose blending therapies, and escalated epidemic proportions of hypertension. According to the World Health Organization, around 1.13 billion people worldwide are suffering from hypertension, most (two-thirds) living in low- and middle-income countries. Moreover, irregular lifestyle with food habits, changing lifestyle, aging regardless of demography, and supplemented stress level coupled with rising research and development for the modern drugs also supporting the growth of the renin-inhibitor market. However, side effects such as cough, diarrhea, nervousness, constipation, dizziness, weakness, and increased risk of genericization are estimated to hinder the growth of the global market over the forecast period.
The resin-inhibitor market is anticipated to record a significant CAGR over the forecast period i.e. 2020-2028. The market is segmented by product type & by application, out of which, the age above 66 segment of the application sector is anticipated to hold leading shares in the renin-inhibitor market on account of rising cardiovascular diseases and hypertension cases among this segment. According to the National Centre for Health Statistics. From 2015 to 2016, the prevalence of hypertension was 29.0% and increased with age: age group 18–39, 7.5%; 40–59, 33.2%; and 60 and over, 63.1%. On the contrary, 300mg/tablet segment of the product type sector is estimated to witness modest growth over the forecast period owing to the treatment of high blood pressure by relaxing blood vessels for a better circulation of the blood. CLICK TO DOWNLOAD SAMPLE REPORT
Growth Drivers
Frequency of Cardiovascular Diseases Among the Geriatric Population
The renin-inhibitor market is estimated to observe a significant growth on account of the frequency of cardiovascular diseases among the geriatric population as aged individuals continue to become prone to hypertension and other cardiovascular complications. Additionally, an individual who suffers from hypertension is very susceptible to other complications such as aneurysm and heart failure. Thus, requires early diagnosis as well as management by using renin-inhibitor drugs.
Rampant Research and Development for the Antihypertensive Drugs Driving the Global Market
An upsurge in research related to antihypertensive drugs in developing economies coupled with pulmonary hypertensive practices offering training programs for people, a high predominance of incessant illness, initiatives are taken by the government and the growing commonness of hypertension in youth population in emerging economies are anticipated to fuel the growth of renin-inhibitors over the forecast period., i.e. 2020-2028.
Restraints
Side Effects of Renin-Inhibitors
Growth of renin-inhibitors is expected to be hampered by the side effects of drugs such as cough, diarrhea, nervousness, constipation, dizziness, weakness, and increased risk of genericization coupled with recent patent expirations.
Market Segmentation
Our in-depth analysis of the renin-inhibitors market includes the following segments:
By Product Type
- 150mg/Tablet
- 300mg/Tablet
By Application
- Below 45
- 46-55
- 55-65
- Above 66
By Region
Based on geographically, the renin-inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
The market in North America is anticipated to hold the leading share during the forecast period on account of a rise in the prevalence of hypertension and chronic kidney disorders. Conversely, the presence of major companies propels the renin-inhibitor market growth in the North America region. On the contrary, the Asia-Pacific region is anticipated to witness high growth in the global market over the forecast period owing to the high incidences of cardiovascular diseases, government initiatives taken for the healthcare sector, and high population pool.
The renin-inhibitors market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
- The Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Top Featured Companies Dominating the Market
- Johnson & Johnson
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer
- Bio-Rad Laboratories Inc.
- Sanofi
- Lupin
- Merck & Co.
- Astra Zeneca
- Daiichi Sankyo
- Novartis
- Boehringer Ingelheim International GmbH
